- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03282942
Cardiovascular Effects of Aerobic and Strength Training in Hypertensive Middle-aged Individuals
Effects of Aerobic or Strength Training on Cardiovascular, Endothelial Response, and Blood Flow in Hypertensive Middle Ages Individuals: a Randomized Controlled Clinical Trial.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasilien
- Universidade Federal do Rio Grande do Sul
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Study inclusion criteria consisted of the following: 1) Individuals should use antihypertensive medication; 2) 30-59 years of age.
Exclusion Criteria:
The following aspects were regarded as exclusion criteria: 1) body mass index (BMI) up to 40 kg/m2; 2) regular engagement in any type of physical exercise training in the past 6 months prior to inclusion in the study; 3) symptomatic peripheral arterial occlusive disease; 4) aortic insufficiency or stenosis more than stage I; 5) hypertrophic obstructive cardiomyopathy; 6) congestive heart failure (>NYHA II); 7) uncontrolled cardiac arrhythmia with hemodynamic relevance; 7) change of antihypertensive medication in the past 4 weeks prior to inclusion in the study; 8) indication of unstable coronary artery disease. 9) use of tobacco products.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Exercise training protocols
Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST).
Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
|
Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition. The following exercises will compose the strength training protocol:
Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks.
The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
|
|
Ingen indgriben: Control Group
The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood pressure
Tidsramme: End of 12-week exercise period
|
24-h Ambulatory blood pressure
|
End of 12-week exercise period
|
|
Endothelial Function
Tidsramme: End of 12-week exercise period
|
Flow mediated dilation to reactive hyperemia
|
End of 12-week exercise period
|
|
Endothelium derived factors
Tidsramme: End of 12-week exercise period
|
The plasma levels of NOx and ET-1 will be determined by enzyme-linked immunosorbent assay
|
End of 12-week exercise period
|
|
Inflammatory Profile
Tidsramme: End of 12-week exercise period
|
The inflammatory profile was accessed trough the cytokines and chemokines levels
|
End of 12-week exercise period
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 69373217.3.0000.5347
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Arteriel hypertension
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Pittsburgh; Sheba Medical Center; Mount Sinai Hospital, Canada og andre samarbejdspartnereRekrutteringTwin Reversal Arterial Perfusion SyndromeSpanien, Tyskland, Israel, Belgien, Holland, Canada, Forenede Stater, Østrig, Frankrig, Italien, Det Forenede Kongerige
-
Nanfang Hospital, Southern Medical UniversityRekrutteringBevacizumab | Hepatecellular carcinoma | QL1706 | RALOX-HAIC (Hepatic Arterial Infusion Chemoterapi med Raltitrexed og Oxaliplatin) | Type VP3/4 Portalvene Tumor Trombose | Iparomlimab og Tuvonralimab-injektionKina
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
BackBeat Medical IncIkke rekrutterer endnuHypertension, systolisk | Hypertension (HTN) | Hjertesvigt med bevaret ejektionsfraktion (HFpEF)Georgien
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
Kliniske forsøg med Strength training group
-
Milton S. Hershey Medical CenterAktiv, ikke rekrutterendeMobilitetsbegrænsning | Gå, besværForenede Stater
-
Hacettepe UniversityAfsluttetRestitution, psykologiskTyrkiet (Türkiye)
-
Riphah International UniversityRekrutteringAutismespektrumforstyrrelsePakistan
-
Children's Cancer Hospital Egypt 57357AfsluttetMedulloblastom, barndom | BarnekræftEgypten
-
Istanbul University - Cerrahpasa (IUC)Afsluttet
-
Inonu UniversityAfsluttetMultipel sclerose | Multipel sklerose tilbagefalder overførelse | Balance svækkelse, gangforstyrrelser, træthed | Multipel sklerose BeningKalkun
-
Chinese University of Hong KongThe Hong Kong Polytechnic UniversityUkendt
-
Hacettepe UniversityAfsluttetEffekten af Humeral Head Depressor Muscle Co-Activation Training i form af funktionelle resultaterKirurgi | Rotator Cuff RiverKalkun
-
Boston VA Research Institute, Inc.Centers for Disease Control and PreventionAfsluttetAggression | Posttraumatisk stresslidelseForenede Stater
-
Cairo UniversityIkke rekrutterer endnuKronisk ankelinstabilitet, CAIEgypten